We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) has been benefiting from solid momentum in its clinical diagnostics business, driven by growth in the Leica Biosystems and Beckman Colter Diagnostics units. The company has been witnessing positive responses for its new products like Aperio GT 450 DX and Access NT ProBNP, which both received the FDA 510K clearance. Also, solid momentum in the molecular diagnostics business, led by increased respiratory and non-respiratory disease tests, has been buoying the Diagnostics segment.
Solid momentum and market share gains for its Cepheid business also bode well for the segment. Core revenues from the Diagnostics segment increased 3% year over year in 2024. For 2025, Danaher anticipates core revenues from the Diagnostics segment to remain flat or increase in low-single-digits on a year-over-year basis.
Danaher believes in adding complementary businesses to its portfolio via acquisitions. In December 2023, DHR acquired Abcam plc, a global supplier of protein consumables, for approximately $5.7 billion. This acquisition expanded the company’s Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio boosted Danaher’s healthcare product portfolio. Acquisitions boosted the company’s total revenues by 2% in 2024.
DHR remains committed to rewarding shareholders through dividend payouts and share buybacks. For instance, it paid out dividends worth $768 million and $821 million in 2024 and 2023, respectively. Also, in February 2025, the company hiked its dividend by 18.5% to 32 cents per share.
Downsides of DHR
Despite the positives, sluggish demand across pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end markets. Core revenues from the Life Sciences segment declined 2% on a year-over-year basis in 2024.
Also, weakness in the company’s Biotechnology segment raises concerns. Sluggish demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment. The segment’s core revenues declined 4.5% on a year-over-year basis in 2024.
High debt levels have also been a concern for Danaher. It exited fourth-quarter 2024 with a long-term debt of $15.5 billion. Its current liabilities were $6.8 billion, higher than the cash equivalents of $2.1 billion. Also, interest expenses in 2024 remained high at $278 million.
DHR’s Price Performance
In the past year, this Zacks Rank #3 (Hold) company has declined 19% compared with the industry’s 16% decrease.
Image Source: Zacks Investment Research
Key Picks
Some better-ranked stocks from the same space are discussed below:
The company delivered a trailing four-quarter average earnings surprise of 19.4%. In the past 60 days, the Zacks Consensus Estimate for MD’s 2025 earnings has increased 5.4%.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank #2 (Buy). COR delivered a trailing four-quarter average earnings surprise of 5%.
In the past 60 days, the consensus estimate for Cencora’s fiscal 2025 (ending September 2025) earnings has increased 1.5%.
Enhabit, Inc. (EHAB - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.9%.
In the past 60 days, the Zacks Consensus Estimate for EHAB’s 2025 earnings has increased 27.6%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
Danaher Corporation (DHR - Free Report) has been benefiting from solid momentum in its clinical diagnostics business, driven by growth in the Leica Biosystems and Beckman Colter Diagnostics units. The company has been witnessing positive responses for its new products like Aperio GT 450 DX and Access NT ProBNP, which both received the FDA 510K clearance. Also, solid momentum in the molecular diagnostics business, led by increased respiratory and non-respiratory disease tests, has been buoying the Diagnostics segment.
Solid momentum and market share gains for its Cepheid business also bode well for the segment. Core revenues from the Diagnostics segment increased 3% year over year in 2024. For 2025, Danaher anticipates core revenues from the Diagnostics segment to remain flat or increase in low-single-digits on a year-over-year basis.
Danaher believes in adding complementary businesses to its portfolio via acquisitions. In December 2023, DHR acquired Abcam plc, a global supplier of protein consumables, for approximately $5.7 billion. This acquisition expanded the company’s Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio boosted Danaher’s healthcare product portfolio. Acquisitions boosted the company’s total revenues by 2% in 2024.
DHR remains committed to rewarding shareholders through dividend payouts and share buybacks. For instance, it paid out dividends worth $768 million and $821 million in 2024 and 2023, respectively. Also, in February 2025, the company hiked its dividend by 18.5% to 32 cents per share.
Downsides of DHR
Despite the positives, sluggish demand across pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end markets. Core revenues from the Life Sciences segment declined 2% on a year-over-year basis in 2024.
Also, weakness in the company’s Biotechnology segment raises concerns. Sluggish demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment. The segment’s core revenues declined 4.5% on a year-over-year basis in 2024.
High debt levels have also been a concern for Danaher. It exited fourth-quarter 2024 with a long-term debt of $15.5 billion. Its current liabilities were $6.8 billion, higher than the cash equivalents of $2.1 billion. Also, interest expenses in 2024 remained high at $278 million.
DHR’s Price Performance
In the past year, this Zacks Rank #3 (Hold) company has declined 19% compared with the industry’s 16% decrease.
Image Source: Zacks Investment Research
Key Picks
Some better-ranked stocks from the same space are discussed below:
Pediatrix Medical Group, Inc. (MD - Free Report) presently sports a Zacks Rank # 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The company delivered a trailing four-quarter average earnings surprise of 19.4%. In the past 60 days, the Zacks Consensus Estimate for MD’s 2025 earnings has increased 5.4%.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank #2 (Buy). COR delivered a trailing four-quarter average earnings surprise of 5%.
In the past 60 days, the consensus estimate for Cencora’s fiscal 2025 (ending September 2025) earnings has increased 1.5%.
Enhabit, Inc. (EHAB - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.9%.
In the past 60 days, the Zacks Consensus Estimate for EHAB’s 2025 earnings has increased 27.6%.